News | December 18, 2025
Godavari Biorefineries launches US biotech arm to advance novel cancer therapies
The move strengthens GBL’s clinical-stage presence in the United States
The move strengthens GBL’s clinical-stage presence in the United States
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Now a test that offers new precision in prostate cancer detection
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
Subscribe To Our Newsletter & Stay Updated
